Bestatin

TargetMol
Product Code: TAR-T1257
Supplier: TargetMol
CodeSizePrice
TAR-T1257-5mg5mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1257-10mg10mg£123.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1257-25mg25mg£160.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1257-50mg50mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1257-100mg100mg£306.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1257-500mg500mg£655.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Ubenimex competitively inhibits many aminopeptidases, including B, N and leucine aminopeptidases. Ubenimex is a microbial metabolite and dipeptide with potential immunomodulatory and antitumor activities. Aminopeptidases has been implicated in the process of cell adhesion and invasion of tumor cells. Therefore, inhibiting aminopeptidases may partially attribute to the antitumor effect of ubenimex. This agent also activates T lymphocyte, macrophage, and bone marrow stem cell as well as stimulates the release of interleukin-1 and -2, thus further enhances its antitumor activity.
CAS:
58970-76-6
Formula:
C16H24N2O4
Molecular Weight:
308.378
Pathway:
Microbiology/Virology; Immunology/Inflammation; Metabolism;
Purity:
0.9963
SMILES:
CC(C)CC(NC(=O)C(O)C(N)Cc1ccccc1)C(O)=O
Target:
Aminopeptidase; Antibacterial; Antibiotic; LTR

References

1. Sekine K, et al. Leukemia, 1999, 13(5), 729-734. 2. Yoneda J, et al. Clin Exp Metastasis, 1992, 10(1), 49-59. 3. Aozuka Y, et al. Cancer Lett, 2004, 216(1), 35-42. 4. Math? G, et al. Biomed Pharmacother, 1991, 45(2-3), 49-54. 5. Chen X, et al. J Natl Cancer Inst, 2003, 95(14), 1053-1061. 6. Jiang T Y, Feng X F, Fang Z, et al. PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer[J]. Cancer Letters. 2020 7. Jiang T Y, Pan Y F, Wan Z H, et al. PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma[J]. Science Translational Medicine. 2020, 12(562).